---
title: "Nanjing Pharmaceutical Group Company Limited (600713.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600713.SH.md"
symbol: "600713.SH"
name: "Nanjing Pharmaceutical Group Company Limited"
industry: "Health Care Distributors"
datetime: "2026-05-20T16:47:56.380Z"
locales:
  - [en](https://longbridge.com/en/quote/600713.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600713.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600713.SH.md)
---

# Nanjing Pharmaceutical Group Company Limited (600713.SH)

## Company Overview

Nanjing Pharmaceutical Group Company Limited engages in the drug distribution businesses in China. It also involved in the wholesale and retail of medical device distribution; pharmaceutical logistics; and internet drug retail business. The company was formerly known as NanJing Pharmaceutical Company Limited and change its name to Nanjing Pharmaceutical Group Company Limited in December 2025. Nanjing Pharmaceutical Group Company Limited was founded in 1951 and is based in Nanjing, China.

| Item | Detail |
|------|--------|
| Industry | Health Care Distributors |
| Exchange | CN Market |
| Website | [www.njyy.com](https://www.njyy.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.53)**

**Industry**: Health Care Distributors

| Metric | Value |
|--------|-------|
| Industry Ranking | 12 / 23 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.06% |  |
| Net Profit YoY | 5.63% |  |
| P/B Ratio | 0.93 |  |
| Dividend Ratio | 3.26% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6844574053.80 |  |
| Revenue | 54657219340.31 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 8.65% | B |
| Profit Margin | 1.14% | C |
| Gross Margin | 6.28% | E |
| Revenue YoY | 1.06% | C |
| Net Profit YoY | 5.63% | C |
| Total Assets YoY | 6.05% | C |
| Net Assets YoY | 5.71% | C |
| Cash Flow Margin | -241.50% | E |
| OCF YoY | 1.06% | C |
| Turnover | 1.58 | A |
| Gearing Ratio | 76.16% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Nanjing Pharmaceutical Group Company Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.06%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "5.63%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.93",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "3.26%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6844574053.80",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "54657219340.31",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "8.65%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "1.14%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "6.28%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "1.06%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "5.63%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.05%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "5.71%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-241.50%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "1.06%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "1.58",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "76.16%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 10.73 | 5/23 | 13.39 | 12.05 | 11.58 |
| PB | 0.91 | 9/23 | 1.02 | 0.98 | 0.95 |
| PS (TTM) | 0.12 | 2/23 | 0.13 | 0.13 | 0.12 |
| Dividend Yield | 3.33% | 5/23 | 3.34% | 3.21% | 3.09% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | HUADONG MEDICINE (000963.SZ) | B | C | A | B | C | B |
| 02 | SINOPHARM(CNCM LTD) (600511.SH) | C | C | A | C | C | B |
| 03 | TIBET PHARMA (600211.SH) | A | C | C | B | C | B |
| 04 | Shanghai Pharma (601607.SH) | C | C | A | D | C | C |
| 05 | GYBYS (600332.SH) | C | C | A | C | C | C |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600713.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600713.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600713.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600713.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**